Skip to main content

Table 2 GPA and MPA incident patients’ characteristics at inclusion, by inclusion period

From: Evolution of therapeutic management of patients with ANCA associated vasculitis in France after licensing Rituximab use

 

GPA

 

MPA

 

GPA, MPA, and undetermined

 

Inclusion period

2010–2012

N = 694

2014–2017

N = 668

P-value

2010–2012

N = 283

2014–2017

N = 463

P-value

2010–2012

N = 1,024

2014–2017

N = 1,214

P-value

Age (years), mean (± SD)

59.8 (± 15.5)

60.8 (± 15.7)

0.180

66.0 (± 13.4)

67.5 (± 13.2)

0.123

61.7 (± 15.3)

63.8 (± 15.1)

0.001

No. of men (%)

386 (55.6%)

376 (56.3%)

0.804

147 (51.9%)

247 (53.4%)

0.709

556 (54.3%)

664 (54.7%)

0.850

  1. P-value in bold type means that the difference in the characteristics between the two inclusion periods is statistically significant